Bob Copeland, Ph.D.

Bob Copeland, Ph.D., founded Accent Therapeutics, Inc. in September 2017 and serves as its President and Chief Scientific Officer. He is also President of the independent consulting firm, Ki Consultant, LLC. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. Bob serves on a number of advisory boards within industry, academia, professional societies and professional journals. His research interest is in elucidating the determinants of drug recognition by their biological targets and the use of this information in the discovery and design of new medicines. He has contributed to drug discovery and development efforts leading to 19 investigational new drugs entering human clinical trials. Bob has contributed more than 200 publications to the scientific literature, holds 14 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology. In 2016, he was elected a Fellow of the American Association for the Advancement of Science (AAAS) and in 2020 he was elected a Fellow of the Royal Society of Chemistry. Bob received his B.S. in Chemistry from Seton Hall University, his Ph.D. in Chemistry from Princeton University, and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology.